- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07793708
Older Adults' Recovery Dynamics After Cardiac Surgery (ODYSSEY)
Clinical, Functional, and Biological Characterization of Resilience in Older Adults Undergoing Cardiac Surgery: ODYSSEY Study - Pilot Phase
Population aging has increased the number of older adults exposed to interventions with high physiological demand, which are associated with frequent adverse outcomes such as delirium, organ dysfunction, and delayed functional recovery. Current clinical tools, such as frailty assessments, help identify higher-risk populations but do not adequately explain the marked individual variability in recovery or accurately predict who will develop complications. This variability may be partly explained by individual resilience, defined as the ability to recover toward, return to, or even surpass a prior functional state after an acute stressor. Evidence suggests that biological mechanisms related to aging influence resilience; however, biomarkers and integrated clinical models capable of characterizing and potentially modulating resilience in humans remain limited. Therefore, a standardized clinical platform is needed to characterize physiological resilience and its determinants, generating actionable knowledge to improve risk stratification, guide interventions, and optimize recovery in older adults.
To this end, a single-center prospective cohort study will be conducted at Clinica Bicentenario Santiago, including individuals aged ≥65 years who are independent or have mild dependency and are undergoing elective cardiac surgery requiring sternotomy for valvular and/or coronary artery disease, recruited between 2026 and 2027. Participants will undergo a baseline assessment 2-3 weeks before surgery; an early postoperative assessment focused on the systematic recording of clinical outcomes, including delirium and organ dysfunction; and longitudinal follow-up to characterize recovery after discharge. Follow-up assessments will include frailty, intrinsic capacity (the composite of an individual's physical and mental capacities across the cognitive, locomotor, psychological, vitality, and sensory domains), functional status, health-related quality of life, and perceived fatigability, according to the prespecified assessment schedule.
In addition, blood samples will be collected at three time points (baseline, 24 hours postoperatively, and one month after surgery) to measure plasma levels of growth differentiation factor 15 (GDF-15), a biomarker associated with aging-related biological stress and systemic responses to tissue injury. It is projected that at least 75 participants will be recruited over a 12-month period, allowing characterization of baseline clinical and functional profiles, the frequency of postoperative complications and organ dysfunction, trajectories of recovery, and associations between baseline characteristics, biological markers, and subsequent recovery outcomes.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Felipe H Salech, MD PhD
- Número de teléfono: +56998739448
- Correo electrónico: fhsalech@gmail.com
Ubicaciones de estudio
-
-
-
Santiago, Chile
- Clinica Bicentenario Red Salud
-
Contacto:
- Felipe Salech, MD PhD
- Número de teléfono: +56998739448
- Correo electrónico: fhsalech@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Older adults (≥ 65 años) undergoing elective cardiac surgery via median sternotomy, including coronary artery bypass grafting (CABG) and/or valvular surgery.
- Independence in basic daily activities, defined as a Barthel Index score ≥80.
Exclusion Criteria:
- Emergency surgery for any indication
- Terminal illness, defined as a life expectancy of less than 12 months
- History of cognitive impairment, defined as a documented diagnosis of dementia and/or current treatment with memantine or donepezil
- Advanced hepatic or renal failure, defined as Child-Pugh class C liver disease or chronic dialysis
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Frailty
Periodo de tiempo: 1 month after discharge
|
Frailty measured by the Physical Frailty Phenotype (Fried Frailty Phenotype).
The total score ranges from 0 to 5, with higher scores indicating greater frailty.
Participants are classified as robust (score 0), prefrail (score 1-2), or frail (score 3-5).
|
1 month after discharge
|
|
Functional status assessed by the Barthel Index
Periodo de tiempo: 1, 6, and 12 months after discharge
|
Functional status in basic activities of daily living will be assessed using the Barthel Index.
The total score ranges from 0 to 100 points, with higher scores indicating greater independence in basic activities of daily living and therefore better functional status.
|
1, 6, and 12 months after discharge
|
|
Functional status assessed by the Lawton-Brody Instrumental Activities of Daily Living Index
Periodo de tiempo: 1, 6, and 12 months after hospital discharge
|
Functional status in instrumental activities of daily living will be assessed using the Lawton-Brody Instrumental Activities of Daily Living Index.
The scale evaluates independence in instrumental activities of daily living, with higher scores indicating greater independence and therefore better functional status.
|
1, 6, and 12 months after hospital discharge
|
|
Cognitive capacity assessed by the Montreal Cognitive Assessment
Periodo de tiempo: 1 month after hospital discharge
|
Cognitive capacity will be assessed using the Montreal Cognitive Assessment (MoCA), a cognitive screening instrument evaluating multiple cognitive domains.
The total score ranges from 0 to 30 points, with higher scores indicating better cognitive performance.
|
1 month after hospital discharge
|
|
Cognitive capacity assessed by the AD8 Dementia Screening Interview
Periodo de tiempo: 1 month after hospital discharge
|
Cognitive capacity will also be assessed using the AD8 Dementia Screening Interview (AD8), an 8-item screening instrument for cognitive change.
The total score ranges from 0 to 8 points, with higher scores indicating greater cognitive impairment and therefore a worse outcome.
|
1 month after hospital discharge
|
|
Locomotor capacity assessed by the Short Physical Performance Battery
Periodo de tiempo: 1 month after hospital discharge
|
Locomotor capacity will be assessed using the Short Physical Performance Battery (SPPB), which evaluates standing balance, gait speed, and repeated chair stands.
The total score ranges from 0 to 12 points, with higher scores indicating better physical performance.
|
1 month after hospital discharge
|
|
Psychological capacity assessed by the Patient Health Questionnaire-9
Periodo de tiempo: 1 month after hospital discharge
|
Psychological capacity will be assessed using the Patient Health Questionnaire-9 (PHQ-9), a 9-item instrument assessing depressive symptoms.
The total score ranges from 0 to 27 points, with higher scores indicating greater severity of depressive symptoms and therefore a worse outcome.
|
1 month after hospital discharge
|
|
Vitality assessed by the Mini Nutritional Assessment-Short Form
Periodo de tiempo: 1 month after hospital discharge
|
Vitality will be assessed using the Mini Nutritional Assessment-Short Form (MNA-SF), a nutritional screening instrument for older adults.
The total score ranges from 0 to 14 points, with higher scores indicating better nutritional status.
|
1 month after hospital discharge
|
|
Visual capacity assessed by the Integrated Care for Older People vision screening tool
Periodo de tiempo: 1 month after hospital discharge
|
Visual capacity will be assessed using the World Health Organization Integrated Care for Older People (ICOPE) vision screening tool.
Participants will be classified according to the ICOPE screening assessment as having no evidence of visual impairment or evidence of visual impairment.
|
1 month after hospital discharge
|
|
Hearing capacity assessed by the Integrated Care for Older People hearing screening tool
Periodo de tiempo: 1 month after hospital discharge
|
Hearing capacity will be assessed using the World Health Organization Integrated Care for Older People (ICOPE) hearing screening tool.
Participants will be classified according to the ICOPE screening assessment as having no evidence of hearing impairment or evidence of hearing impairment.
|
1 month after hospital discharge
|
|
Perceived fatigability assessed by the Pittsburgh Fatigability Scale
Periodo de tiempo: 1 month after hospital discharge
|
Perceived fatigability will be assessed using the Pittsburgh Fatigability Scale (PFS), which evaluates anticipated physical and mental fatigue associated with 10 standardized activities.
Each activity is rated from 0 to 5 points, with 0 indicating no fatigue and 5 indicating extreme fatigue.
Physical fatigability and mental fatigability are scored separately, each ranging from 0 to 50 points.
Higher scores indicate greater perceived fatigability and therefore a worse outcome.
|
1 month after hospital discharge
|
|
Health-related quality of life assessed by the EuroQol 5-Dimension 3-Level questionnaire
Periodo de tiempo: 1 month after hospital discharge
|
Health-related quality of life will be assessed using the EuroQol 5-Dimension 3-Level (EQ-5D-3L) questionnaire.
The descriptive system evaluates five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension has three response levels: no problems, some or moderate problems, and extreme problems.
In addition, participants will rate their overall health using the EuroQol Visual Analogue Scale (EQ VAS), which ranges from 0 to 100, with higher scores indicating better perceived health status.
|
1 month after hospital discharge
|
|
Organ dysfunction severity assessed by the Sequential Organ Failure Assessment score
Periodo de tiempo: During the first 4 postoperative days
|
Organ dysfunction severity will be assessed using the Sequential Organ Failure Assessment (SOFA) score, which evaluates respiratory, coagulation, hepatic, cardiovascular, central nervous system, and renal function.
The total score ranges from 0 to 24 points, with higher scores indicating greater organ dysfunction and therefore a worse outcome.
|
During the first 4 postoperative days
|
|
Postoperative Delirium
Periodo de tiempo: During the first 4 postoperative days
|
Presence of postoperative delirium assessed during the immediate postoperative period using standardized clinical criteria.
|
During the first 4 postoperative days
|
|
Survival
Periodo de tiempo: Up to 12 months after hospital discharge.
|
All-cause mortality.
|
Up to 12 months after hospital discharge.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Growth Differentiation Factor 15 (GDF-15)
Periodo de tiempo: 24 hours after cardiac surgery and 1 month after hospital discharge
|
Plasma levels of Growth Differentiation Factor 15 (GDF-15) measured as a biomarker of biological stress and resilience.
|
24 hours after cardiac surgery and 1 month after hospital discharge
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- P-42.2025
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .